Finally moving forward in adult ALL

Research output: Contribution to journalComment/debatepeer-review

1 Scopus citations


In this issue of Blood, Dhédin et al from the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) show that young to middle-aged adults who receive a pediatric-intensive chemotherapy regimen for treatment of Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph-neg ALL) do not appear to require an allogeneic stem cell transplant (alloSCT) if they achieve a good response on minimal residual disease (MRD) testing after induction therapy. Patients who are not good MRD responders however, achieve better outcomes with alloSCT than their counterparts who do not receive alloSCT.

Original languageEnglish (US)
Pages (from-to)2453-2454
Number of pages2
Issue number16
StatePublished - Apr 16 2015

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Finally moving forward in adult ALL'. Together they form a unique fingerprint.

Cite this